|
|
Volumn 83, Issue SUPPL. 1, 2006, Pages
|
|
Regulatory challenges for new formulations of controlled substances in today's environment
|
|
Author keywords
Abuse liability; Drug development; Formulation; Regulation; Risk management
|
|
Indexed keywords
4 HYDROXYBUTYRIC ACID;
BUPRENORPHINE;
BUPRENORPHINE PLUS NALOXONE;
BUTORPHANOL TARTRATE;
FENTANYL CITRATE;
ISOTRETINOIN;
MU OPIATE RECEPTOR AGONIST;
MU OPIATE RECEPTOR ANTAGONIST;
OPIATE;
OXYBATE SODIUM;
PENTAZOCINE;
TALWIN NX;
THALIDOMIDE;
ARTICLE;
CATAPLEXY;
DRUG ABUSE;
DRUG APPROVAL;
DRUG BIOAVAILABILITY;
DRUG CONTAMINATION;
DRUG CONTRAINDICATION;
DRUG CONTROL;
DRUG FORMULATION;
DRUG INDUSTRY;
DRUG INFORMATION;
DRUG MEGADOSE;
DRUG MISUSE;
DRUG MONITORING;
DRUG OVERDOSE;
DRUG RELEASE;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
ERYTHEMA NODOSUM LEPROSUM;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
INFORMATION DISSEMINATION;
METERED DOSE INHALER;
NARCOLEPSY;
OPIATE ADDICTION;
POSTOPERATIVE PAIN;
PRIORITY JOURNAL;
RISK MANAGEMENT;
TERATOGENICITY;
CHEMISTRY, PHARMACEUTICAL;
DRUG AND NARCOTIC CONTROL;
DRUG COMPOUNDING;
DRUG DESIGN;
HUMANS;
NARCOTICS;
RISK MANAGEMENT;
UNITED STATES;
|
|
EID: 33646029116
PISSN: 03768716
EISSN: None
Source Type: Journal
DOI: 10.1016/j.drugalcdep.2006.02.001 Document Type: Article |
|
Times cited : (19)
|
|
References (10)
|
